Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 22,011 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
Interventions: Carillon Mitral Contour System, Guideline Directed Heart Failure Medication; Device · Other
Lead sponsor: Cardiac Dimensions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 75
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
Interventions: high dose rate brachytherapy; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
Interventions: Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT); Drug · Other
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Lynwood, California • Hialeah, Florida • Miami, Florida + 6 more

Conditions: Gastric Cancer
Interventions: small RNA-seq or array, ENLIGHT Assay; Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Psychological Distress, Suicidal Ideation
Interventions: Flourish; Device
Lead sponsor: Candice Biernesser; Other
Eligibility: 11 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Bay Village, Ohio • Pittsburgh, Pennsylvania

Conditions: Bladder Cancer
Interventions: Stent placement, Alvimopan; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: T Cell Non-Hodgkin Lymphoma
Interventions: Senza5 CART5; Drug
Lead sponsor: Vittoria Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Upper GI Bleeding
Interventions: HemoPill acute; Device
Lead sponsor: Stony Brook University; Other
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Athlete Support
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Peripheral Vascular Disease, Peripheral Arterial Disease
Interventions: Evero DCB, Paclitaxel DCB; Combination Product
Lead sponsor: Cook Research Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 15
States / cities: Long Beach, California • New Haven, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: Cancer, Radiation Therapy, Dietary Intake
Interventions: Mobile food record using myCircadian Clock app; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
Interventions: Retifanlimab, Gemcitabine, Docetaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Post Traumatic Stress Disorder, Depression - Major Depressive Disorder
Interventions: Psilocybin + MBCT therapy, Active Comparator: Psilocybin with Support Only; Combination Product
Lead sponsor: Anthony P King; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cardiovascular Diseases
Interventions: MBCT-T, Booster Mindfulness Sessions, Website Support; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumor, Advanced Lymphoma
Interventions: AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect; Drug
Lead sponsor: Adlai Nortye Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Hackensack, New Jersey • The Bronx, New York • Greenville, South Carolina + 1 more

Conditions: High Blood Pressure
Interventions: Home Blood Pressure Machine, 24-Hour Blood Pressure Machine; Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 13 Years to 18 Years
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cardiovascular Diseases
Interventions: d-Coaching; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Francisco, California • Decatur, Georgia

Conditions: Stroke
Interventions: Technology-Supported Hand Training, Pamphlet-Supported Hand Activity; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anterior Cruciate Ligament Rupture
Interventions: Blood Flow Restriction using Delfi Personalized Tourniquet System; Device
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: 12 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Unemployment
Interventions: Purposeful Pathways, Transitional Work; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Hines, Illinois • Bedford, Massachusetts • Dallas, Texas

Conditions: Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
Interventions: Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
Interventions: Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation, Sham transcranial magnetic stimulation; Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Acute Myeloid Leukemia
Interventions: Venetoclax, Gemtuzumab, Ziftomenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: IgA Nephropathy
Interventions: BHV-1400; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Farmington, Connecticut • Miami Lakes, Florida • Orlando, Florida + 9 more

Search by objective public record fields.

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers

Flourish in Schools Pilot Study

A Study of Surgical Techniques During Cystectomy

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

Detection of Blood in the GI Lumen With HemoPill Acute

Athlete Needs Assessment & Focus Groups

EVERO Drug-coated Balloon (DCB) Randomized Trial

Capturing Food Intake in Patients Undergoing Radiation Therapy for Cancer

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Mindfulness-based Psilocybin Therapy for PTSD

HARP Mindfulness Study

First in Human, Dose Escalation Study of AN4005

Home BP Monitoring

Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans

Telerehabilitation for Post-Stroke Hand Function

BFRT in Adolescents After ACL Reconstruction

Evaluating the Efficacy of a Vocational Counseling Intervention to Improve Occupational Functioning and Employment Quality Among Veterans With Mental Health and Substance Use Disorders

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

One-Day cTBS Over the Precuneus

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Study of BHV-1400 in IgA Nephropathy